Zalcitabine population pharmacokinetics: Application of radioimmunoassay

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 2, 1998, Pages 409-413

  Adams, John M ^a,b   Shelton, Mark J ^a,b   Hewitt, Ross G ^b,c,d   DeRemer, Mary ^a   DiFrancesco, Robin ^a   Grasela, Thaddeus H ^a   Morse, Gene D ^a,b,c,d  

^a UNIVERSITY AT BUFFALO   (United States)

^b ERIE COUNTY MEDICAL CENTER   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZALCITABINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; FEMALE; HUMANS; MALE; RADIOIMMUNOASSAY; ZALCITABINE;

EID: 0031915694     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Balzarini, J., R. Pauwels, M. Baba, P. Herdewijn, E. De Clercq, S. Broder, and D. G. Johns. 1988. The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochem. Pharmacol. 37:897-903.
2. Balzarini, J., R. Pauwels, P. Herdewijn, E. De Clercq, D. A. Cooney, G. J. Kang, M. Dalal, D. G. Johns, and S. Broder. 1986. Potent and selective anti-HTLV-III/LAV activity of 2′,3′-dideoxycytidine, the 2′,3′-unsaturated derivative of 2′,3′-dideoxycytidine. Biochem. Biophys. Res. Commun. 140: 735-742.
3. Beal, S. L., and L. B. Sheiner. 1980. The NONMEM system. Am. Stat. 34:118.
4. Beal, S. L., and L. B. Sheiner (ed.). 1992. NONMEM users' guides. NON-MEM Project Group, University of California at San Francisco, San Francisco.
5. Bozzette, S. A., and D. D. Richman. 1990. Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytidine. Am. J. Med. 88:24S-26S.
6. Broder, S. 1990. Pharmacodynamics of 2′,3′-dideoxycytidine: an inhibitor of human immunodeficiency virus. Am. J. Med. 88(Suppl. 5B):2S-7S.
7. Burger, D. M., H. Rosing, C. H. H. ten Napel, T. Duyts, P. L. Meenhorst, J. W. Mulder, C. H. W. Koks, A. Bult, and J. H. Beijnen. 1994. Application of a radioimmunoassay for determination of levels of zalcitabine (ddC) in human plasma, urine, and cerebrospinal fluid. Antimicrob. Agents Chemother. 38:2763-2767.
8. Chen, C. H., and Y. C. Cheng. 1989. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 264:11934-11937.
9. Cooney, D. A., M. Dalal, H. Mitsuya, J. B. McMahon, M. Nadkarni, J. Balzarini, S. Broder, and D. G. Johns. 1986. Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem. Pharmacol. 35:2065-2068.
10. Dubinsky, R. M., R. Yarchoan, M. Dalakas, and S. Broder. 1989. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2′,3′-dideoxycytidine (ddC). Muscle Nerve 12:856-860.
11. Eron, J. J., V. A. Johnson, D. P. Merrill, T. C. Chou, and M. S. Hirsch. 1992. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro. Antimicrob. Agents Chemother. 36:1559-1562.
12. Fischl, M. A., K. Stanley, A. C. Collier, J. M. Arduino, D. S. Stein, J. E. Feinberg, J. D. Allan, J. C. Goldsmith, W. G. Powderly, and the NIAID AIDS Clinical Trials Group. 1995. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann. Intern. Med. 122:24-32.
13. Fischl, M. A., R. M. Olson, S. E. Follansbee, J. P. Lalezari, D. H. Henry, P. T. Frame, S. C. Remick, M. P. Salgo, A. H. Lin, and C. Nauss-Karol. 1993. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann. Intern. Med. 118: 762-769.
14. Gustavson, L. E., E. K. Fukuda, F. A. Rubio, and A. W. Dunton. 1990. A pilot study of the bioavailability and pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS or AIDS-related complex. J. Acquired Immune Defic. Syndr. 3:28-31.
15. Hoffmann-La Roche Inc. 1992. Package insert. HIVID (zalcitabine). Hoffmann-La Roche Inc., Nutley, N.J.
16. Huang, E. L., R. G. Hewitt, M. Shelton, and G. D. Morse. 1996. Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease. Pharmacotherapy 16:222-229.
17. Jajoo, H. K., S. M. Bennett, and D. M. Kornhauser. 1992. Thermospray liquid chromatographic-mass spectrometric analysis of anti-AIDS nucleosides: quantification of 2′,3′-dideoxycytidine in plasma samples. J. Chromatogr. Biomed. Appl. 577:299-304.
18. Kalin, J. R., and D. Hill. 1988. Determination of 2′,3′-dideoxyadenosine, 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine in biological samples. J. Chromatogr. Biomed. Appl. 431:184-191.
19. Klecker, R. W., J. M. Collins, R. C. Yarchoan, R. Thomas, McAtee, S. Broder, and C. E. Myers. 1988. Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. J. Clin. Pharmacol. 28:837-842.
20. Magnani, M., L. Rossi, M. Bianchi, L. Cucchiarini, and V. Stocchi. 1989. Reversed-phase liquid chromatographic determination of 2′,3′-dideoxycytidine in human blood samples. J. Chromatogr. Biomed. Appl. 491:215-220.
21. Mathes, L. E., G. Muschik, L. Demby, P. Polas, D. Weiss Mellini, H. J. Issaq, and R. Sams. 1988. High-performance liquid chromatographic determination of 2′,3′-dideoxycytidine and 3′-azido-3′-deoxythymidine in plasma using a column-switching technique. J. Chromatogr. Biomed. Appl. 432:346-351.
22. Meng, T. C., M. A. Fischl, A. M. Boota, S. A. Spector, D. Bennett, Y. Bassiakos, S. Lai, B. Wright, and D. D. Richman. 1992. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. Ann. Intern. Med. 116:13-20.
23. Merigan, T. C., G. Skowron, S. A. Bozzette, D. Richman, R. Uttamchandani, M. Fischl, R. Schooley, M. Hirsch, W. Soo, and C. Pettinelli. 1989. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. Ann. Intern. Med. 110:189-194.
24. Merigan, T. C., G. Skowron, and the ddC Study Group of the AIDS Clinical Trial Group of the National Institute of Allergy and Infectious Diseases. 1990. Safety and tolerance of dideoxycytidine as a single agent. Am. J. Med. 88(Suppl. 5B):11S-5S.
25. Pizzo, P. A., K. Butler, F. Balis, E. Brouwers, M. Hawkins, J. Eddy, M. Einloth, J. Falloon, R. Husson, and P. Jarosinski. 1990. Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. J. Pediatr. 117:799-808.
26. Plagemann, P. G. W., and C. Woffendi. 1989. Dideoxycytidine permeation and salvage by mouse leukemia cells and human erythrocytes. Biochem. Pharmacol. 38:3469-3475.
27. Qian, M., A. R. Swagler, M. Mehta, C. T. Vishwanathan, and J. M. Gallo. 1992. Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) drugs. III. 2′,3′-Dideoxycytidine (ddC) and zidovudine in monkeys. Pharm. Res. 9:224-227.
28. Rubino, F. R., T. Crews, W. A. Garland, and E. K. Fukuda. 1988. Quantification of dideoxycytidine in human plasma by gas chromatography/mass spectrometry. Biomed. Environ. Mass Spectrom. 17:399-404.
29. Sheiner, L. B., and S. L. Beal. 1982. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-bayesian methods. J. Pharm. Sci. 71:1344-1348.
30. Shelton, M., A. M. O'Donnell, and G. D. Morse. 1993. Zalcitabine. Ann. Pharmacother. 27:480-489.
31. Skowron, G., S. A. Bozzette, L. Lim, C. B. Pettinelli, H. H. Schaumburg, J. Arezzo, M. A. Fischl, W. G. Powderly, D. J. Gocke, and D. D. Richman. 1993. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann. Intern. Med. 118:321-330.
32. Spector, S. A., D. Ripley, and K. Hsia. 1989. Human immunodeficiency virus inhibition is prolonged by 3′-azido-3′-deoxythymidine alternating with 2′,3′-dideoxycytidine compared with 3′-azido-3′-deoxythymidine alone. Antimicrob. Agents Chemother. 33:920-923.
33. Starnes, M. C., and Y. Cheng. 1987. Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J. Biol. Chem. 262:988-991.
34. Szebeni, J., S. M. Wahl, G. V. Betageri, L. M. Wahl, S. Gartner, M. Popovic, R. J. Parker, C. D. Black, and J. N. Weinstein. 1990. Inhibition of HIV-1 in monocyte/macrophages cultures by 2′,3′-dideoxycytidine-5′-triphosphate, free and in liposomes. AIDS Res. Hum. Retroviruses 6:691-702.
35. Törnevik, Y., and S. Eriksson. 1990. 2′,3′-Dideoxycytidine toxicity in cultured human CEM T lymphoblasts: effects of combination with 3′-azido-3′-deoxythymidine and thymidine. Mol. Pharmacol. 38:237-243.
36. Ullman, B., T. Coons, S. Rockwell, and K. McCartan. 1988. Genetic analysis of 2′,3′-dideoxycytidine incorporation into cultured human T lymphoblasts. J. Biol. Chem. 263:12391-12396.
37. Yarchoan, R., H. Mitsuya, C. E. Myers, and S. Broder. 1989. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N. Engl. J. Med. 321:726-738.
38. Yarchoan, R., C. F. Perno, R. V. Thomas, R. W. Klecker, J. P. Allain, R. J. Wills, N. McAtee, M. A. Fischl, R. Dubinsky, and M. C. McNeely. 1988. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet i:76-81.